Citadel Advisors LLC Boosts Holdings in USANA Health Sciences, Inc. (USNA)

Citadel Advisors LLC grew its holdings in USANA Health Sciences, Inc. (NYSE:USNA) by 267.0% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 13,278 shares of the company’s stock after acquiring an additional 9,660 shares during the period. Citadel Advisors LLC owned about 0.05% of USANA Health Sciences worth $766,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also bought and sold shares of USNA. Renaissance Technologies LLC grew its stake in shares of USANA Health Sciences by 10.6% in the second quarter. Renaissance Technologies LLC now owns 1,948,266 shares of the company’s stock worth $124,884,000 after acquiring an additional 186,600 shares in the last quarter. Arrowstreet Capital Limited Partnership grew its stake in shares of USANA Health Sciences by 711.5% in the second quarter. Arrowstreet Capital Limited Partnership now owns 91,409 shares of the company’s stock worth $5,859,000 after acquiring an additional 80,145 shares in the last quarter. FMR LLC grew its stake in shares of USANA Health Sciences by 3.9% in the second quarter. FMR LLC now owns 1,598,143 shares of the company’s stock worth $102,441,000 after acquiring an additional 60,033 shares in the last quarter. Old Mutual Global Investors UK Ltd. lifted its position in shares of USANA Health Sciences by 29.7% during the 2nd quarter. Old Mutual Global Investors UK Ltd. now owns 239,680 shares of the company’s stock worth $15,363,000 after purchasing an additional 54,831 shares during the last quarter. Finally, Schroder Investment Management Group lifted its position in shares of USANA Health Sciences by 9.0% during the 2nd quarter. Schroder Investment Management Group now owns 572,186 shares of the company’s stock worth $36,734,000 after purchasing an additional 47,448 shares during the last quarter. Institutional investors and hedge funds own 43.82% of the company’s stock.

In related news, Director Myron W. Wentz sold 164,916 shares of the business’s stock in a transaction on Tuesday, November 21st. The shares were sold at an average price of $66.40, for a total value of $10,950,422.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Gilbert A. Fuller sold 1,710 shares of the business’s stock in a transaction on Thursday, October 26th. The shares were sold at an average price of $67.01, for a total transaction of $114,587.10. Following the completion of the sale, the director now directly owns 1,710 shares of the company’s stock, valued at $114,587.10. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 806,060 shares of company stock valued at $51,895,822. Corporate insiders own 53.20% of the company’s stock.

USNA has been the subject of several recent analyst reports. Pivotal Research lifted their price objective on shares of USANA Health Sciences from $70.00 to $80.00 and gave the stock a “buy” rating in a research report on Wednesday, October 25th. BidaskClub cut shares of USANA Health Sciences from a “hold” rating to a “sell” rating in a research report on Thursday, November 2nd.

USANA Health Sciences, Inc. (NYSE:USNA) traded up $0.15 during trading on Friday, hitting $70.90. 62,183 shares of the stock traded hands, compared to its average volume of 103,017. The stock has a market cap of $1,701.10, a PE ratio of 18.76 and a beta of 1.08. USANA Health Sciences, Inc. has a 1-year low of $52.55 and a 1-year high of $72.80.

USANA Health Sciences (NYSE:USNA) last released its quarterly earnings data on Tuesday, October 24th. The company reported $1.02 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.91 by $0.11. The business had revenue of $261.77 million during the quarter, compared to analysts’ expectations of $259.52 million. USANA Health Sciences had a net margin of 8.79% and a return on equity of 26.38%. The company’s revenue for the quarter was up 3.0% on a year-over-year basis. During the same period in the previous year, the company earned $2.40 EPS. analysts anticipate that USANA Health Sciences, Inc. will post 3.7 earnings per share for the current year.

WARNING: “Citadel Advisors LLC Boosts Holdings in USANA Health Sciences, Inc. (USNA)” was first published by Community Financial News and is the property of of Community Financial News. If you are viewing this piece on another publication, it was copied illegally and reposted in violation of U.S. and international trademark & copyright legislation. The original version of this piece can be read at https://www.com-unik.info/2017/12/10/citadel-advisors-llc-boosts-holdings-in-usana-health-sciences-inc-usna.html.

USANA Health Sciences Profile

USANA Health Sciences, Inc develops and manufactures science-based nutritional and personal care products. The Company operates as a direct selling company in two geographic regions: Americas and Europe, and Asia Pacific, which includes three sub-regions: Southeast Asia Pacific, Greater China and North Asia.

Want to see what other hedge funds are holding USNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for USANA Health Sciences, Inc. (NYSE:USNA).

Institutional Ownership by Quarter for USANA Health Sciences (NYSE:USNA)

What are top analysts saying about USANA Health Sciences Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for USANA Health Sciences Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit